1. Home
  2. CING vs CYPH Comparison

CING vs CYPH Comparison

Compare CING & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CING

Cingulate Inc.

HOLD

Current Price

$5.23

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Logo Cypherpunk Technologies Inc.

CYPH

Cypherpunk Technologies Inc.

HOLD

Current Price

$1.16

Market Cap

73.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CING
CYPH
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
73.3M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
CING
CYPH
Price
$5.23
$1.16
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$34.50
N/A
AVG Volume (30 Days)
132.2K
1.8M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
56.47
103.87
EPS
N/A
N/A
Revenue
N/A
$1,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.16
$0.49
52 Week High
$11.89
$3.70

Technical Indicators

Market Signals
Indicator
CING
CYPH
Relative Strength Index (RSI) 58.37 79.45
Support Level $5.08 $1.10
Resistance Level $5.54 $1.32
Average True Range (ATR) 0.27 0.09
MACD 0.03 0.05
Stochastic Oscillator 82.22 82.88

Price Performance

Historical Comparison
CING
CYPH

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

Share on Social Networks: